SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11249
  • 2
    Lamm DL, van der Meijden APM, Akaza H et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995; 2 (Suppl. 2): 2335
  • 3
    Kurth KH, Bouffioux C, Sylvester R et al. Treatment of superficial bladder tumors: achievement and needs. Eur Urol 2000; 37 (Suppl. 3): 19
  • 4
    Akaza H, Koiso K, Ozono S et al. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 2003; 33: 38290
  • 5
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 905
  • 6
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 121623
  • 7
    Hinotsu S, Akaza H, Isaka S et al. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006; 67: 5459
  • 8
    Badalament RA, Herr HW, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 4419
  • 9
    Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001; 165: 148891
  • 10
    Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138: 2958
  • 11
    Herr HW. Is maintenance Bacillus Calmette-Guérin really necessary? Eur Urol 2008; 54: 9713
  • 12
    Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86: 181826
  • 13
    The Japan Pharmaceutical Manufacturers Association. Japanese Ministerial Ordinance on Standards for Conducting Clinical Trials on Pharmaceuticals. Tokyo: Elsevier Japan K.K. 1997 Ordn. (MHW), No. 28 (in Japanese)
  • 14
    Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975; 31: 10315
  • 15
    Akaza H, Isaka S, Koiso K et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 1987; 20 (Suppl.): S916
  • 16
    Hinotsu S, Akaza H, Isaka S et al. Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer – the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. Jpn J Cancer Chemother 2002; 29: 7380 (in Japanese)
  • 17
    Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer: the 6th trial of the Japanese Urological Cancer Research Group (JUCRG) – a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 2004; 45: 6005
  • 18
    Japan Clinical Oncology Group. National Cancer Institute-Common Toxicity Criteria (NCI-CTC)Version 2.0. Japanese Version of Japan Clinical Oncology Group 2nd Edn. 2001
  • 19
    Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med 2009; 28: 332946
  • 20
    Gray RJ. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 1990; 46: 93102
  • 21
    Saint F, Irani J, Patard JJ et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 8838
  • 22
    van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166: 47681
  • 23
    Bohle A, Bock PR. Intravesical bacillus Calmette-Guérin versus Mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63: 6827
  • 24
    Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 25
    Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010; 36: 195205
  • 26
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J. Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. European Association of Urology (EAU). Eur Urol 2008; 54: 30314
  • 27
    American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer: (Stage Ta, T1, and Tis): 2007 Update. [homepage on the internet]. Available at:http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bc. Accessed 11 August 2010
  • 28
    Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005; 66: 90107
  • 29
    National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology TM: Bladder Cancer: Including upper tract tumors and urothelial carcinoma of the prostate v.l.2009. [homepage on the internet]. Available at:http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed 31 January 2009
  • 30
    The Japanese Urological Association. Bladder Cancer Clinical Practice Guideline. Tokyo: Igaku Tosho Syuppan Co., Ltd., Tokyo, 2009: (in Japanese)
  • 31
    Lamm DL, Colombel M, Persad R et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol 2008; (Suppl. 7): 65166
  • 32
    Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 24756
  • 33
    Lamm D, Böhle A, Palou J et al. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 24756. Eur Urol 2010; 57: e7–9; author reply e10–1
  • 34
    Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 41029
  • 35
    Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E et al. Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 12427
  • 36
    Mugiya S, Ozono S, Nagata M et al. Long-term outcome of a low-dose intravesical bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005; 35: 3959